We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Model-Based ATG Dosing Successfully Accelerates CD4+ Reconstitution in CD34+ Selected Allogeneic HCT

MedXY Editorial Team•Jan 13, 2026•Hematology-Oncology
antithymocyte globulinhematopoietic cell transplantationImmune Reconstitutionprecision medicine

Introduction: Balancing GVHD Prevention and Immune Reconstitution

The landscape of allogeneic hematopoietic cell transplantation (HCT) has been defined by a precarious balance between preventing graft-versus-host disease (GVHD) and ensuring rapid immune recovery. Ex vivo CD34+ selection, a process that physically removes T-cells from the donor graft, has emerged as a powerful technique to minimize the risk of chronic GVHD without the need for prolonged immunosuppression. However, this method has historically been hampered by delayed immune reconstitution (IR), specifically the slow recovery of CD4+ T-cells, which increases the patient’s vulnerability to opportunistic infections and non-relapse mortality (NRM).

The Role of Antithymocyte Globulin

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Gradual Maturation of the B-Cell Receptor Repertoire After Pediatric Hematopoietic Stem Cell Transplantation: Insights into Early Immune ReconstitutionThis study reveals early establishment of a diverse naïve B-cell receptor repertoire within 3 months post-pediatric HSCT, followed by gradual antigen-experienced maturation over 24 months, reflecting physiological B-cell development and supSep 18, 2026Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis: A Precision Medicine ImperativeClonal hematopoiesis of indeterminate potential (CHIP) poses a novel cardiovascular risk. This article explores challenges and strategies for designing cardiovascular outcomes trials tailored to CHIP’s genetic heterogeneity and clinical comSep 15, 2026Rapid Immunoassay for Molecular Subphenotyping in Pediatric Acute Cardiorespiratory Failure: Clinical Implications and Future DirectionsRapid immunoassay-based classifiers accurately identify hyper- and hypoinflammatory subphenotypes in critically ill children, preserving prognostic and predictive utility and enabling precision therapies in acute pediatric cardiorespiratorySep 13, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Coordinated Precision Care for Rare Genetic Obesity: European Expert Consensus on Centers of Expertise and Structured MonitoringEuropean experts recommend designated centers, structured diagnostic pathways, and real‑world monitoring to deliver precision therapies (MC4R agonists) safely and equitably to people with rare genetic forms of obesity.Aug 25, 2026
Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification InsightsA multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognosticaAug 24, 2026
Inflammatory Phenotypes in Severe Pneumonia: Bridging Clinical Insights and Mouse Models for Targeted TherapiesThis article explores hyperinflammatory and hypoinflammatory phenotypes in severe pneumonia, their clinical impact, and translational mouse models that inform precision therapeutic strategies.Aug 23, 2026